Activated Tregs suppress Mreg DCs via CTLA-4 and migrate to draining lymph nodes, thereby limiting tumor antigen presentation and impeding the initiation of anti-tumor adaptive immune responses. This evidence concerns the gene CTLA4 and neoplasm.